Aim DPF2 has been reported to be involved in pathogenesis of leukaemia and oncogenic activity.However,the role of DPF2 in oncogenesis and pathogenesis of pancreatic cancer remains unclear.Therefore,the present research aims to investigate the effects of DPF2-RNAi on proliferation,apoptosis and cell cycle regulation of a pancreatic cell line,PANC-1 cells.Methods The lentivirus-mediated DPF2-RNAi was employed to knockdown DPF2 expression in PANC-1 cells,and the role of DPF2-RNAi in proliferation,apoptosis and cell cycle regulation of the PANC-1 cells was examined through MTT assay,colony formation assay and flowcytometry assay.Results The lentivirus-mediated DPF2-RNAi middle and high doses(2 μL and 4 μL)significantly decreased the expression of DPF2 in the PANC-1 cells.DPF2-RNAi decreased cell viability and colony formation,and increased apoptosis of the PANC-1 cells.Besides,DPF2-RNAi induced the S-phase arrest and decreased G2/M phase population of the PANC-1 cells.Conclusions DPF2 may play a crucial role in proliferation,apoptosis and cell cycle regulation of PANC-1 cells.Knockdown of DPF2 through lentivirus-mediated DPF2-RNAi may provide experimental basis for finding a new method for therapy of pancreatic cancer.

OBJECTIVEThis study investigated the expression of BNIP3 in salivary adenoid cystic carcinoma (SACC) and its correlations to the clinicopathological features and prognosis of patients with SACC. The role of BNIP3 in the progress of hypoxia-induced autophagy was elucidated.

METHODSThe expression levels of BNIP3, hypoxia inducible factor (HIF)-1α, and LC3 in 65 SACC cases were detected by immunohistochemical staining method, and the correlation between the expression of BNIP3 and the clinicopathological features in SACC was analyzed. In addition, the correlations of BNIP3 gene expression with HIF-1α and LC3 gene expression were analyzed. The survival rate of patients with SACC was evaluated by univa-riate survival analysis.

RESULTSBNIP3 was considerably expressed in SACC in all three histological patterns, and was positive in 41 cases (63.1%). BNIP3 gene expression was significantly correlated with histological grade (P=0.001) and HIF-1α gene expression (P=0.011). By contrast, BNIP3 gene expression was not significantly correlated with LC3 gene expression (P=
0.167). The overall survival rate of patients with negative BNIP3 expression was better than that of patients with positive BNIP3 expression (P<0.05).

CONCLUSIONSBNIP3 might play a vital role in the tumorigenesis of SACC and may be a new target for gene therapy.
.

Autophagy ; Carcinoma, Adenoid Cystic ; Contraindications ; Humans ; Hypoxia-Inducible Factor 1, alpha Subunit ; Membrane Proteins ; Prognosis ; Proto-Oncogene Proteins ; Salivary Gland Neoplasms

Objective To evaluate the clinical performance of chemiluminescent immunoassay (CLIA) on anti-nuclear antibody(ANA) specific autoantibodies testing.Methods A multi-center clinical study A total of 811 Sera samples were collected from 6 collaborating hospitals during the period of April to July 2016, and tested with CLIA and line immunoassay (LIA) in parallel for autoantibodies to ribonucleoprotein(RNP), smith antigen(Sm), SSA/Ro60,SSB/La, centromere protein B(CENPB), double-stranded DNA(dsDNA), nucleosome(Nuc), and ribosome P protein(Rib-P).The positive rate,specificity and qualitative coincidence rate for each antibody between CLIA and LIA methods were analyzed.All discrepant samples for systemic lupus erythematosus (SLE) highly specific autoantibodies (including anti-Sm, dsDNA, Nuc and Rib-P) were retested by enzyme linked immunosorbent assay (ELISA) and further analyzed with SLE disease cohort using McNemar test.Results The positive rate and specificity of CLIA and LIA for antibodies to ANA specific antigens were comparable.Excellent qualitative coincidence were found between CLIA and LIA for the detection of anti-RNP, SSA/Ro60, SSB/La and CENPB (Kappa>0.75), while the coincidence rate foranti-Sm, dsDNA, Nuc and Rib-P detection were moderate (0.4

In recent years, the clinical experts consensuses or guidelines of ankylosing spondylitis (AS)/spondyloarthritis (SpA) have been constantly updated, but to better understand and practice, patient self-participation management is one of the key points to improve the level of diagnosis and treatment. Through questionnaire survey of these patients, we screened out the most concerned issues, and established the AS/SpA patient practice guideline working group with multidisciplinary physicians and patients. Fifteen opinions, as the AS/SpA patient practice guidelines, are proposed in accordance with the relevant principles of the "WHO guidelines development manual" , and with the international normative process.